TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female age 14-45, with 10 to 100 comedones (noninflammatory lesions), 10 to 50 inflammatory lesions (papules or pustules), and not more than 35 nodules (\<5mm) on the face).~Exclusion Criteria:~* Standard contraindications for use of combined oral contraceptives (class label) plus~* Subjects with acne and atopia, comedonal acne or acne conglobate, sandpaper acne or acne with multiple large nodes, cysts, fistular comedones, or abscessing fistular ducts~* Use of comedogenic covering cream, comedogenic sunscreens, other sex hormone preparations or any other anti-acne therapy (eg, light therapy, oleic acids, chemical pellings, mechanical extraction of comedones)~* Acne therapy with sex hormone preparations given over 3 months or longer and proved to be unsuccessful~* Preparations that have had an acne-inducing effect, eg, iodinated or bromated drugs, tuberculostatics, lithium, Vitamin B1, B6, B12, D3, corticoids, ACTH, anabolics, quinine, disulfiram, methoxypsoralen, phenobarbital, phenytoin, trimethadione, thyroid depressants, and certain oily cosmetics

- Gender: FEMALE
- Minimum Age: 14 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Dopamine Versus Vasopressin for Treatment of Low Blood Pressure in Low Birth Weight Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Infants less than 24 hours of age~* Infants with birth weight of \<1001 grams and/or gestational age of \<29 weeks~* Not initiated on any continuous pressor therapy prior to enrollment~* Intravenous line in place~* Outborn infants meeting eligibility criteria~Exclusion Criteria:~* Infants not meeting eligibility criteria~* Infants with life-threatening congenital defects~* Infants with congenital hydrops~* Infants with frank hypovolemia (perinatal history consistent with decreased circulating blood volume plus clinical signs of hypovolemia)~* Infants with other unresolved causes of hypotension (air leaks, lung overdistention, or metabolic abnormalities).

- Gender: ALL
- Minimum Age: None
- Maximum Age: 24 Hours
- Healthy Volunteers: f

Study Arms:
- Dopamine treatment (Type: ACTIVE_COMPARATOR): Dopamine treatment beginning at 5 mcg/kg/min and titrated by 5 mcg/kg/min to effect up to maximum of 20 mcg/kg/min
- Vasopressin treatment (Type: ACTIVE_COMPARATOR): Arginine Vasopressin treatment beginning at 0.01 units/kg/hr and titrated up by 0.01 units/kg/hr to effect up to a maximum of 0.04 units/kg/hr
- Comparison Arm (Type: NO_INTERVENTION): Infants who did not require vasopressor support for hypotension during the first 24 hours of life

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female adults (age \> / = 18 years)~* Diagnosed with one of the following types and stages of tumors: stage III or IV breast cancer; stage III or IV ovarian cancer; stage III or IV bladder cancer; stage III or IV lung cancer; metastatic prostate cancer; stage III or IV diffuse large B-cell lymphoma; multiple myeloma.~* Planned to receive primary prophylaxis with filgrastim biosimilar (EP2006) at the first cycle of chemotherapy (regardless of line of chemotherapy); or receiving secondary prophylaxis with filgrastim biosimilar (EP2006) irrespective of chemotherapy cycle.~* Treated with commercially available filgrastim biosimilar per physician's best clinical judgment and per current European filgrastim biosimilar (EP2006) label.~* Female patients must be either post-menopausal for one year or surgically sterile or using effective contraceptive methods such as barrier method with spermicide or an intra-uterine device. Oral contraceptive use is allowed.~* Informed written consent to participate in the study by patients or their legal guardian.~Exclusion Criteria:~* Patients with myeloid malignancies, with the exception of multiple myeloma.~* Sensitivity to filgrastim biosimilar or any other CSF.~* Hypersensitivity to E. coli-derived proteins.~* Radiotherapy to ≥ 20% of total body bone.~* Infection within two weeks of starting current line of chemotherapy.~* Patients with several medical condition(s) that in view of the investigator prohibits participation in the study.~* Patients with willfully negligent nonadherence to their cancer treatment.~* Use of any investigational agent in the 30 days prior to enrollment.~* Women of childbearing potential not using the contraception method(s) described above.~* Women who are breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Only 1 group (Type: None): Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients suffering from inflammatory bowel disease: Crohn's disease/Ulcerative colitis~2. Age 18-40~3. Willing to provide informed consent~Exclusion Criteria:~1. Have history of vaccination to hepatitis A~2. Have other autoimmune disease~3. Have any malignancy~4. Have acute infectious disease~5. Unwilling to provide consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- IBD patients (Type: EXPERIMENTAL): Patients diagnosed with IBD~-\> receive Epaxal Berna (virosomal hepatitis A vaccine)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with locally advanced BCC and metastatic BCC~* Patients with adequate bone marrow, liver, and renal function~Exclusion Criteria:~* Patients who had had major surgery within 4 weeks of initiation of study medication~* Patients unable to take oral drugs or with lack of physical integrity of the upper gastrointestinal tract, or known malabsorption syndromes.~* Patients with concurrent medical conditions that may interfere or potentially affect the interpretation of the study.~* Patients with neuromuscular disorders or are on concurrent treatment with drugs that may cause muscle damage.~* Patients who were on concurrent therapy with other anti-neoplastic agents.~* Patients who had taken part in an experimental drug within 4 weeks of initiation of study medication.~* Pregnant or nursing (lactating) women~* Women of child bearing potential unwilling to use 2 forms of highly effective contraception throughout the study and for 3 months after the last treatment~* Fertile males not willing to use condoms throughout the study and for 3 months after the last treatment.~* Patients who were unwilling or unable to comply with the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDE225 200 mg (Type: EXPERIMENTAL): The study was double blinded and enrolled at least 50 evaluable patients in the 200 mg LDE225 arm. The efficacy and safety of LDE225 was analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 200 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.
- LDE225 800 mg (Type: EXPERIMENTAL): The study was double blinded and enrolled at least 100 evaluable patients in the 800 mg LDE225 arm. The efficacy and safety of LDE225 was analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 800 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Antipsychotic Combination Treatment of Olanzapine and Amisulpride to Monotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with schizophrenia and schizoaffective disorder according to International Classification of Diseases (ICD-10);~* age 18-65;~* Positive and Negative Symptom Scale Total-Score ≥ 70 and two items of the positive symptom subscale ≥4.~* voluntary treatment after written informed consent~* legal capacity~* exclusion of pregnancy by laboratory test (Beta HCG)~Exclusion Criteria:~* participation in other interventional studies with drugs or medical devices~* first episode patients~* physical disease that might have effects on the conduct or evaluation of the trial~* contraindications to medication according to experts information~* oversensitivity to active substance or other component of the drugs used~* known clozapine resistance~* suicidal ideation~* pregnancy or lactation~* which of pregnancy or absence save contraception~* dependency to sponsor or investigator~* institutionalization through judicial or regulatory order~* oversensitivity to placebo (mannite/aerosil)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Olanzapine or Placebo (Type: ACTIVE_COMPARATOR): None
- Amisulpride or Placebo (Type: ACTIVE_COMPARATOR): None
- Olanzapine and Amisulpride (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Of Itraconazole In Chronic Cavitary Pulmonary Aspergillosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
1. Inclusion Criteria:~   1. Clinical symptoms: -presence of chronic pulmonary/systemic symptoms lasting ≥ six weeks.~  2. Radiological findings:~      * Evidence of slowly progressive pulmonary lesions over weeks-months including cavities with surrounding inflammation.~     * presence of intracavitary mass with a surrounding crescent of air,and presence of pleural thickening in peripheral lesions.~  3. Microbiological/Immunological findings: Positive results in the aspergillus precipitin test, demonstration of aspergillus hyphae in sputum or BAL fluid or cultures of BAL/sputum growing aspergillus species.~2. The diagnosis of CCPA will be made if~   1. Patient satisfies at least 1, 2a or 2b and/ or any of the 3rd criteria.~  2. FNAC from the cavity wall will be considered in atypical cases~3. Exclusion Criteria:~   1. Invasive aspergillosis~  2. Allergic broncho-pulmonary aspergillosis (ABPA)~  3. Active tuberculosis or malignancy~  4. Pregnant females

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Itraconazole (Type: ACTIVE_COMPARATOR): Role of itraconazole in CCPA
- treatment in cavitary pulmonary aspergillosis (Type: EXPERIMENTAL): Patients in this arm are given conservative management with antitussives, brochial artery embolisation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* PDY6045 or PDY6046 participant who:~  * completed the week 24 visit of either study PDY6045 or PDY6046,~ * was still meeting eligibility criteria for receiving treatment,~ * had agreed to continue stable dose of Interferon-β \[IFN-β\] or Glatiramer Acetate \[GA\] and consented to continue on treatment.~Exclusion Criteria:~* Any known condition or circumstance that would have prevented in the investigator's opinion, compliance or completion of the study~The above information is not intended to contain all considerations relevant to patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Placebo + IFN-β (Type: PLACEBO_COMPARATOR): Placebo (for teriflunomide) once daily concomitantly with interferon-β \[IFN-β\] for 24 additional weeks
- Teriflunomide 7 mg + IFN-β (Type: EXPERIMENTAL): Teriflunomide 7 mg once daily concomitantly with interferon-β \[IFN-β\] for 24 additional weeks
- Teriflunomide 14 mg + IFN-β (Type: EXPERIMENTAL): Teriflunomide 14 mg once daily concomitantly with interferon-β \[IFN-β\] for 24 additional weeks
- Placebo + GA (Type: PLACEBO_COMPARATOR): Placebo (for teriflunomide) once daily concomitantly with glatiramer acetate \[GA\] for 24 additional weeks
- Teriflunomide 7 mg + GA (Type: EXPERIMENTAL): Teriflunomide 7 mg once daily concomitantly with glatiramer acetate \[GA\] for 24 additional weeks
- Teriflunomide 14 mg + GA (Type: EXPERIMENTAL): Teriflunomide 14 mg once daily concomitantly with glatiramer acetate \[GA\] for 24 additional weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Pneumonia and Pneumococcal Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children aged 3-60 months assisted as outpatients for non severe community acquired pneumonia and pneumoccocal vaccine and complete immunisation with pneumoccocal vaccine.~Exclusion Criteria:~* Wheezing~* Severe pneumonia~* Pulmonary or cardiovascular chronic disease~* Antibiotic use in the previous two weeks~* Hospitalization for any reason in the previous two weeks

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- BPS (Bacterial Pneumonia Score) (Type: EXPERIMENTAL): Strategy based on BPS guided antibiotic use
- Guideline (Type: ACTIVE_COMPARATOR): Strategy based on enforced guideline guided antibiotic use

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vinorelbine in Treating Children With Recurrent or Refractory Cancers

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically confirmed recurrent or refractory solid malignant tumors of childhood including: Soft tissue sarcoma Rhabdomyosarcoma Nonrhabdomyosarcoma Extraosseous Ewing's sarcoma CNS tumors Astrocytoma Primitive neuroectodermal tumor Atypical teratoid/rhabdoid tumors Ependymoma Recurrent neuroblastoma Measurable disease No more than 2 prior treatment regimens~PATIENT CHARACTERISTICS: Age: 21 and under at diagnosis Performance status: ECOG 0-2 Life expectancy: At least 2 months Hematopoietic: For patients with solid tumors (unless marrow involvement): Absolute neutrophil count (ANC) at least 1000/mm3 Platelet count at least 100,000/mm3 (transfusion independent) Hemoglobin at least 10 g/dL (RBC transfusions allowed) For patients post bone marrow transplantation: ANC at least 1,000/mm3 Platelet count at least 50,000/mm3 (transfusion independent) Hemoglobin at least 10 g/dL (RBC transfusions allowed) Hepatic: Total bilirubin no greater than 1.5 times normal SGOT/SGPT less than 2.5 times normal Renal: Creatinine no greater than 1.5 times normal OR Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min Neurologic: Seizure disorder allowed if well controlled CNS toxicity no greater than grade 2~PRIOR CONCURRENT THERAPY: Biologic therapy: At least 6 months since prior bone marrow transplantation No concurrent immunomodulating agents Chemotherapy: At least 2 weeks since prior chemotherapy (4 weeks for nitrosourea) and recovered No other concurrent chemotherapy Endocrine therapy: No concurrent corticosteroids except for increased intracranial pressure due to CNS tumors Radiotherapy: At least 6 months since prior radiotherapy to craniospinal axis, spine, and/or more than 50% of the bony pelvis Concurrent radiotherapy to localized painful lesions allowed if at least one measurable lesion is not in radiation field Surgery: Not specified Other: No concurrent participation in another CCG, POG, or COG therapeutic study

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Stratum 1 - Soft Tissue Sarcoma (Type: EXPERIMENTAL): See detailed description.
- Stratum 2 - CNS Tumors (Type: EXPERIMENTAL): See detailed description.
- Stratum 3 - Neuroblastoma (Type: EXPERIMENTAL): See detailed description.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of 1 of the following:~  * High-risk acute leukemia, including any of the following:~    * Refractory acute leukemia~   * Acute leukemia beyond first remission~   * Acute leukemia in first remission with poor prognostic features (e.g., chromosomal changes suggesting poor prognosis)~ * Chronic myelogenous leukemia in second chronic, accelerated, or blastic phase~ * Severe aplastic anemia that is not responsive to immunosuppressive therapy~ * Myelodysplastic syndromes, including any of the following:~    * Refractory anemia (RA) or RA with ringed sideroblasts with severe cytopenia~   * RA with excess blasts (RAEB)~   * RAEB in transformation~   * Chronic myelomonocytic leukemia~ * Refractory or relapsed non-Hodgkin or Hodgkin lymphoma~ * Multiple myeloma~ * Biopsy proven measurable solid tumor meeting 1 of the following criteria:~    * Recurrent disease after primary treatment and deemed incurable to standard treatment~   * Metastatic disease for which no known standard therapy that is potentially curative or definitely capable of extending life expectancy exists~* Must have a related HLA-haploidentical mismatched (3/6 or fewer loci) donor available~PATIENT CHARACTERISTICS:~* Karnofsky performance status 70-100%~* Bilirubin \< 2.0 mg/dL~* AST \< 3 times upper limit of normal~* Creatinine \< 2.0 mg/dL~* Ejection fraction \> 40% by MUGA~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics

- Gender: ALL
- Minimum Age: None
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete